Personalis reported a 35% year-over-year increase in total company revenue, driven by a 117% increase in revenue from biopharma business. The company also delivered 561 total molecular tests, a 66% increase compared to the prior quarter. They raised the full year revenue guidance for 2024.
Total company revenue increased by 35% year-over-year, reaching $22.6 million.
Revenue from pharma testing and services grew by 117% year-over-year, totaling $13.2 million.
Net loss decreased by 47% year-over-year, amounting to $12.8 million.
Delivered 561 total molecular tests, a 66% increase compared with the prior quarter.
Personalis provided guidance for the third quarter and revised full year 2024 outlook.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance